[ET Net News Agency, 27 May 2020] Sino Biopharmaceutical Limited (01177) said
"Edaravone and Sodium Chloride Injection" (brand name: Yibitan; specification: 100ml), a
brain neuroprotective agent developed by the group, after obtaining approval for launch
previously as the first generic drug of its kind in China, has just obtained the approval
for supplementary drug registration granted by the National Medical Products
Administration of the People's Republic of China, for a new indication of the suppression
of dysfunction progression of amyotrophic lateral sclerosis (ALS).
Yibitan is the only domestic edaravone preparation with both indications of cerebral
infarction and ALS. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
2.340 -0.090 (-3.704%) Others
27/05/2020 16:53
Sino Biopharm (01177) injection gets approval
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |